Please login to the form below

Not currently logged in

Excellence in Rare Diseases and Orphan Drugs

Sponsored by

Back to Results


Chronicity in Acute Times: Cablivi Access Challenge

by Sanofi Genzyme

Summary of work

In 2018, Sanofi acquired Ablynx, a small biotechnological company focused on the development of nanobody technology, the first being Cablivi for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). This rare, acute and life-threatening disease currently has a treatment landscape which has remained unchanged for many years. With no heritage in rare blood disorders, the Sanofi team, with limited resources, worked to build relationships with clinicians, payers and patient organisations, to develop advocacy for Cablivi and raise awareness of this catastrophic disease.

The team needed to gain insights, identify data gaps and put projects in place, working against the clock to build a robust economic model in what would be an extremely challenging health technology assessment (HTA). The rarity of aTTP meant little data was available, and acute nature of episodes meant proving cost-effectiveness would be our biggest hurdle. There was a clear clinical need and strong advocacy for the drug, so the team worked cross-functionally to find innovative ways to collect data and engage stakeholders to ensure that every patient experiencing an acute episode of aTTP would have access to Cablivi.

Judges' comments

Sanofi Genzyme’s submission was a great market access project. The judges really liked the earthquake imagery, which made it particularly memorable.  The commitment and drive from the cross functional team was impressive.


Greater than the Sum of its Parts - by Jazz Pharmaceuticals

Highly commended


INSPIRE: Improving Outcomes in Paediatric Cardiology - by AbbVie with support from Lucid Group

Palmoplantar Pustulosis Augmented Reality Tool - by Boehringer Ingelheim with support from OPEN Health

RAREfest - by Cambridge Rare Disease Network with support from Havas Life Medicom

Chronicity in Acute Times: Cablivi Access Challenge - by Sanofi Genzyme

Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022